Anti-Met (c-Met) Antibody Picoband®

Overview

This antibody is intended for detection of MET (Hepatocyte growth factor receptor) in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality/clone information, and detection modality.

Vendor notes: Boster Bio Anti-Met (c-Met) Antibody Picoband® catalog # PB9186. Tested in WB applications. This antibody reacts with Human, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Antibody format: Rabbit Polyclonal Rabbit IgG
• Immunogen / epitope context: E.coli-derived human Met recombinant protein (Position: D208-S407). Human Met shares 90% and 91% amino acid (aa) sequences identity with mouse and rat Met, respectively. (reported region: D208-S407).
• Molecular weight context: reported MW: 154 kDa; calculated MW: 155541 MW
• Reactivity: Human,Rat
• Applications: WB

As a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.

Biological background

Hepatocyte growth factor receptor; Hepatocyte growth factor receptor. c-Met, also called MET and hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. It is mapped to 7q31.2. The protein possesses tyrosine kinase activity. MET is a membrane receptor that is essential for embryonic development and wound healing. It induces several biological responses that collectively give rise to a program known as invasive growth. MET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express MET, which allows these cells to grow invasively in order to generate new tissues in an embryo or regenerate damaged tissues in an adult. However, cancer stem cells are thought to hijack the ability of normal stem cells to express MET, and thus become the cause of cancer persistence and spread to other sites in the body. Functional note: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. Reported localization: Membrane; Single-pass type I membrane protein. Expression/tissue context: Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. .

Research relevance and current trends

• Cancer: Researchers commonly examine how MET (Hepatocyte growth factor receptor) relates to this theme using model systems and orthogonal readouts.
• Cancer Susceptibility: Researchers commonly examine how MET (Hepatocyte growth factor receptor) relates to this theme using model systems and orthogonal readouts.
• Epigenetics and Nuclear Signaling: Researchers commonly examine how MET (Hepatocyte growth factor receptor) relates to this theme using model systems and orthogonal readouts.

Common research applications

• Western blotting: compare relative MET (Hepatocyte growth factor receptor) levels across conditions; band patterns may reflect isoforms and processing.

Notes for experimental interpretation

• Specificity notes: No cross reactivity with other proteins.
• Cross-reactivity: No cross-reactivity with other proteins
• Family / similarity context: Belongs to the protein kinase superfamily. Tyr protein kinase family.
• Isoforms and PTMs: Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.
• Controls: Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD/KO samples when available.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.